Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
venerdì, ottobre 02
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Tonix Pharmaceuticals Holding Corp
TNXP
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$9.23
-0.51
-5.24%
Ult. Agg.: Oct 1, 6:55 PM
$9.27
-0.47
-4.8%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Privacy Manager
Tonix Pharmaceuticals Financials
Tonix Pharmaceuticals (TNXP) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Tonix Pharmaceuticals Q2 EPS $(2.44) Beats $(2.64) Estimate, Sales $13.544M Beat $7.723M Estimate
Tonix Pharmaceuticals (NASDAQ:TNXP) reported quarterly losses of $(2.44) per share which beat the analyst consensus estimate of $(2.64) by 7.58 percent. This is a 36.79 percent increase over losses of $(3.86) per share
Benzinga Newsdesk
PRO
Tonix Pharmaceuticals Q1 EPS $(2.93) Misses $(2.43) Estimate, Sales $6.878M Beat $6.100M Estimate
Tonix Pharmaceuticals (NASDAQ:TNXP) reported quarterly losses of $(2.93) per share which missed the analyst consensus estimate of $(2.43) by 20.58 percent. This is a 3.17 percent decrease over losses of $(2.84) per share
Benzinga Newsdesk
Tonix Pharmaceuticals Says Prescriptions For Chronic Pain Drug Top 4,200 Since Launch
Tonix Pharmaceuticals beats expectations, and Tonmya prescriptions grow, with over 4,200 prescriptions since launch.
Vandana Singh
PRO
Tonix Pharmaceuticals Q4 EPS $(3.98) Misses $(3.16) Estimate, Sales $5.390M Beat $2.883M Estimate
Benzinga Newsdesk
PRO
Tonix Pharmaceuticals Q3 EPS $(3.59) Misses $(3.58) Estimate, Sales $3.290M Beat $3.100M Estimate
Tonix Pharmaceuticals (NASDAQ:TNXP) reported quarterly losses of $(3.59) per share which missed the analyst consensus estimate of $(3.58) by 0.14 percent. This is a 84.17 percent increase over losses of $(22.68) per
Benzinga Newsdesk
Crude Oil Moves Higher; US Homebuilder Sentiment Declines In August
Avi Kapoor
